Literature DB >> 8814995

Different roles for plasminogen activators and metalloproteinases in melanoma metastasis.

B M Mueller1.   

Abstract

Malignant human melanoma cells produce many matrix-degrading enzymes, including plasminogen activators and matrix metalloproteinases. These enzymes have substrate specificity for different components of ECM and most of them have been demonstrated to contribute to melanoma cell-mediated dissolution of matrices and to melanoma cell invasion. The degradation of complex matrices in vitro requires the cooperation of proteases with specificity for glycoproteins and collagens. The contribution of proteases to spontaneous melanoma metastasis was studied by overexpressing specific protease inhibitors in human melanoma cells. Overexpression of PAI-2 inhibited the spread of distant metastasis indicating a role for uPA/plasmin in melanoma invasion. Overexpression of TIMP-2, in contrast, reduced the growth rate of subcutaneous tumors, but did not inhibit metastasis, indicating that MMP activities promote melanoma growth in the skin and may not be required for metastatic dissemination. Thus, uPA and MMP activities are involved in different processes, but they both contribute to melanoma malignancy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8814995     DOI: 10.1007/978-3-642-61107-0_5

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  10 in total

Review 1.  Matrix metalloproteinase biology applied to vitreoretinal disorders.

Authors:  C S Sethi; T A Bailey; P J Luthert; N H Chong
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

2.  Role of tissue factor pathway inhibitor-2 (TFPI-2) in amelanotic melanoma (C-32) invasion.

Authors:  S D Konduri; A Tasiou; N Chandrasekar; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

Review 3.  Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target.

Authors:  Eleonore Fröhlich
Journal:  Cell Mol Life Sci       Date:  2010-08-05       Impact factor: 9.261

Review 4.  Osteopontin: an effector and an effect of tumor metastasis.

Authors:  L A Shevde; S Das; D W Clark; R S Samant
Journal:  Curr Mol Med       Date:  2010-02       Impact factor: 2.222

5.  Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma.

Authors:  Li-E Wang; Yu-jing Huang; Ming Yin; Jeffrey E Gershenwald; Victor G Prieto; Jeffrey E Lee; Madeleine Duvic; Elizabeth A Grimm; Qingyi Wei
Journal:  Eur J Cancer       Date:  2010-07-23       Impact factor: 9.162

6.  Angiogenesis and progression in human melanoma.

Authors:  R Ria; A Reale; A Castrovilli; G Mangialardi; F Dammacco; D Ribatti; A Vacca
Journal:  Dermatol Res Pract       Date:  2010-06-06

Review 7.  Angiogenesis in melanoma.

Authors:  Ganapati H Mahabeleshwar; Tatiana V Byzova
Journal:  Semin Oncol       Date:  2007-12       Impact factor: 4.929

8.  High tPA-expression in primary melanoma of the limb correlates with good prognosis.

Authors:  C M Ferrier; S Suciu; W L van Geloof; H Straatman; A M Eggermont; H S Koops; B B Kroon; F J Lejeune; U R Kleeberg; G N van Muijen; D J Ruiter
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

9.  Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression.

Authors:  U B Hofmann; J R Westphal; E T Waas; A J Zendman; I M Cornelissen; D J Ruiter; G N van Muijen
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

10.  Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas.

Authors:  K Airola; T Karonen; M Vaalamo; K Lehti; J Lohi; A L Kariniemi; J Keski-Oja; U K Saarialho-Kere
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.